The COVID-19 pandemic reshaped the pharmaceutical industry in unprecedented ways—disrupting supply chains, accelerating digitalisation, and altering regulatory priorities. As the world moves beyond the immediate crisis, Good Manufacturing Practice (GMP) compliance has also evolved.
In this post-COVID era, regulatory expectations remain high, but the methods, risks, and focus areas in GMP audits have shifted. Here’s what’s changed—and what pharmaceutical companies must do to stay compliant.
1. Increased Focus on Business Continuity and Risk Management
During the pandemic, many companies scrambled to maintain production and supply continuity under extreme constraints. Post-COVID, regulators are now assessing whether business continuity plans (BCPs) are robust, risk-based, and GMP-compliant.
What auditors look for now:
- Documented contingency plans for workforce shortages, lockdowns, and supply disruptions
- Risk assessments tied to critical manufacturing and QA activities
- Alternate suppliers and qualification of backup sources
Key takeaway: BCPs and risk management are no longer optional—they’re an integral part of GMP inspections.
2. Remote and Hybrid GMP Audits
While on-site audits are back, remote and hybrid inspections are here to stay. Regulatory agencies like the FDA, EMA, and MHRA now use remote audits as part of a broader inspection strategy.
What’s changed:
- Expect requests for scanned documents, virtual facility tours, and screen-sharing sessions
- Firms must maintain digital document access and retrieval systems
- Audit readiness now includes having IT systems that support remote inspections
Key takeaway: Being digitally audit-ready is critical for compliance in today’s hybrid audit environment.
3. Greater Scrutiny of Data Integrity
Data integrity was a hot topic before COVID, and it’s even more crucial now, especially with increased reliance on automated systems and remote monitoring.
What auditors expect:
- Secure, validated systems with audit trails
- Role-based access controls and electronic signatures
- Evidence that manual data entry is minimised and verified
Key takeaway: Post-COVID, regulators demand greater traceability and transparency in electronic records and quality systems.
4. Supply Chain and Vendor Qualification Challenges
Global supply disruptions during COVID exposed vulnerabilities in many pharma supply chains. Now, there is tighter scrutiny on supplier qualification, oversight, and distribution practices.
Focus areas include:
- GDP compliance across global supply routes
- Qualification of alternate or emergency suppliers
- Increased documentation for supplier risk assessments and change controls
Key takeaway: GMP compliance now extends more deeply into third-party management and global logistics.
5. Workforce Training and Competency Gaps
COVID caused workforce dislocation, onboarding delays, and limited access to in-person training. Post-COVID audits now evaluate how organisations maintain training quality and operational competency.
Auditors expect to see:
- Shift from passive to interactive, competency-based training
- Documentation of remote training programs and assessments
- Real-time evidence of ongoing qualification and skill checks
Key takeaway: Simply showing that training occurred isn’t enough—proof of effectiveness and understanding is essential.
6. Increased Use of Automation and Digital Tools
To maintain operations with limited staff and distancing protocols, many organisations adopted automation, AI tools, and digital monitoring.
GMP implications include:
- Validation of automated systems
- Updated SOPs reflecting new technologies
- Change management and risk evaluation for digital transformation
Key takeaway: As companies adopt smarter tech, GMP compliance must evolve alongside innovation.
7. Enhanced Emphasis on Environmental and Personal Hygiene Controls
COVID reinforced the critical role of cleanroom practices, PPE usage, and personal hygiene. GMP audits now emphasise how companies maintain these controls under variable conditions.
Updated expectations:
- Clearly defined hygiene SOPs
- Monitoring logs for gowning, sanitation, and cleaning
- Documentation of changes made to meet COVID-era requirements
Key takeaway: Hygiene protocols must be institutionalised, not temporary responses.
The post-COVID world has introduced new risks, technologies, and expectations, and GMP compliance has evolved to reflect these changes. Regulatory authorities are more focused than ever on resilience, digital readiness, and risk-based quality management.
For pharmaceutical companies, this means taking a proactive, systems-driven approach to compliance, backed by modern technology, stronger oversight, and a culture of continuous improvement.
How Q&V Can Help
At Q&V, we support pharma and biotech companies in navigating the new compliance landscape. From remote audit preparation and risk-based QMS enhancement to training modernisation and supplier qualification, our expert team ensures you are not only compliant but future-ready.